<DOC>
	<DOCNO>NCT00022152</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine treat old woman stage IV breast cancer .</brief_summary>
	<brief_title>Vinorelbine Treating Older Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate elderly woman stage IV breast cancer treat oral vinorelbine . - Determine toxicity profile drug patient . - Determine time progression patient treat drug . - Determine quality life patient treated drug . - Assess individual variation response ( toxicity and/or activity ) , pharmacokinetic parameter , and/or biologic correlate due genetic difference enzymes involved transport , metabolism , and/or mechanism action drug patient . OUTLINE : Patients receive oral vinorelbine weekly . Courses repeat every 4 week absence disease progression unacceptable toxicity . Quality life assess baseline completion second course . Patients follow every 3 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV breast cancer Eligible receive first secondline chemotherapy At least 1 unidimensionally measurable lesion At least 20 mm long diameter Must completely outside prior irradiation port unless proof progressive disease completion prior radiotherapy No untreated brain metastasis Current metastatic CNS disease allow previously treat clinically stable study entry No meningeal carcinomatosis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 65 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Total bilirubin great 1.5 time upper limit normal ( ULN ) OR Direct bilirubin normal total bilirubin elevate less 2.5 time ULN Gilbert 's syndrome Renal : Creatinine great 2 time ULN Other : No grade 2 great peripheral neuropathy No significant medical condition would preclude study No active infection within past 2 week No dysphagia inability swallow intact capsule PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 1 prior chemotherapy regimen metastatic disease No prior vinca alkaloid At least 4 week since prior chemotherapy recover Endocrine therapy : Prior hormonal therapy allow No concurrent hormonal therapy Radiotherapy : See Disease Characteristics No prior radiotherapy 25 % bone marrow At least 3 week since prior radiotherapy recover Surgery : At least 3 week since prior major surgery</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>